Spatial compartmentalization of signal transduction in insulin action

Christian A. Baumann and Alan R. Saltiel*

Summary
Insulin resistance is thought to be the primary defect in the pathophysiology of type 2 diabetes. Thus, understanding the cellular mechanisms of insulin action may contribute significantly to developing new treatments for this disease. Although the effects of insulin on glucose and lipid metabolism are well documented, gaps remain in our understanding of the precise molecular mechanisms of signal transduction for the hormone. One potential clue to understanding the unique cellular effects of insulin may lie in the compartmentalization of signaling molecules and metabolic enzymes. We review this evidence, and speculate on how PI-3 kinase-independent and -dependent signaling pathways both diverge from the insulin receptor and converge at discrete targets to insure the specificity of insulin action. BioEssays 23:215–222, 2001. © 2001 John Wiley & Sons, Inc.

Introduction
Diabetes mellitus is a worldwide epidemic, in some ethnic groups affecting over 10% of the population. Type 1 diabetes, defined by an absolute requirement for administration of exogenous insulin, results from the autoimmune destruction of the insulin-secreting pancreatic β cells. Type 2 diabetes usually occurs during adulthood, and is often characterized by a relative resistance to endogenous insulin. The pathophysiology of type 2 diabetes, which accounts for over 90% of patients with the disease, involves defects in three organ systems that conspire together to produce abnormal glucose and lipid metabolism. While there is some uncertainty regarding the primary lesion, or relative importance of different tissues, metabolic defects in liver, peripheral target tissues such as fat and muscle and pancreatic β cells all contribute to the syndrome. Insulin resistance, which is defined as a state of reduced responsiveness to normal circulating concentrations of insulin, is now recognized as a characteristic trait of type 2 diabetes, and contributes to abnormalities in all of these tissues.

A number of prospective epidemiological studies across several population groups have indicated that type 2 diabetes progresses over a continuum of worsening insulin action, beginning with peripheral insulin resistance and ending with a loss of insulin secretion. In most patients, insulin resistance can be detected long before the deterioration of glucose intolerance occurs. Insulin resistance is a quite common state, associated with aging, a sedentary lifestyle, as well as a genetic predisposition. The state seems to be fueled by or perhaps to a certain extent the result of obesity. The ensuing dysregulation of carbohydrate and lipid metabolism that occurs as a consequence of insulin resistance further exacerbates its progression. Beta cells of the pancreas normally compensate for the insulin-resistant state by increasing basal and postprandial insulin secretion. At some point, the beta cells can no longer compensate, failing to respond appropriately to glucose. This ultimately leads to the deterioration of glucose homeostasis, and the development of glucose intolerance. Approximately 5–10% of glucose intolerant patients per year progress to frank diabetes, which continues to worsen as insulin resistance increases. Adipose cells generate more fatty acids, the liver produces more glucose in an unregulated fashion, and the beta cells undergo complete failure, resulting in the late stages of the disease, where high doses of exogenous insulin may be required.

Even in the absence of diabetes, insulin resistance is a key feature of other human disease states. Impaired insulin action coupled with hyperinsulinemia leads to a variety of abnormalities, including elevated triglycerides, low levels of HDL, enhanced secretion of VLDL, disorders of coagulation, increased vascular resistance, changes in steroid hormone levels, attenuation of peripheral blood flow and weight gain. Thus, insulin resistance is often associated with central obesity, hypertension, polycystic ovarian syndrome, dyslipidemia and atherosclerosis. This constellation of symptoms is often referred to as Syndrome X, or Insulin Resistance.
Syndrome. Whether impaired insulin action is directly responsible for all of the symptoms in these patients remains unclear. However, the broad prevalence of insulin resistance, and its association with profound metabolic abnormalities is widely accepted.

Insulin is the most potent anabolic agent known, promoting the synthesis and storage of carbohydrates, lipids and proteins, and inhibiting their degradation and release back into the circulation. Insulin maintains glucose homeostasis by stimulating glucose uptake, utilization and storage in muscle and adipose tissue, and inhibiting glucose output from liver. The hormone also plays an important role in regulating lipid homeostasis, stimulating lipogenesis in fat and liver, and inhibiting lipolysis in fat and muscle. While the underlying cause of insulin resistance remains unknown, investigations have focused on defects in signaling and metabolic pathways. Studies in type 2 diabetic patients have shown that the primary defect in insulin action lies in the regulation of glucose transport in adipose and muscle. This process is mediated by the insulin-stimulated glucose transporter, Glut4.(1)

Insulin action is initiated through the binding to and activation of its tyrosine kinase receptor. At the cellular level, the action of the hormone is characterized by a diverse variety of effects, including changes in vesicle trafficking, stimulation of protein kinases and phosphatases, promotion of cellular growth and differentiation, and activation, or in some cases, repression of transcription. The diverse mechanisms involved in these varied downstream effects suggest that insulin action must involve multiple signaling pathways that diverge at or near the receptor. In this regard, the receptor catalyzes the phosphorylation of several substrates, including the insulin receptor substrate (IRS) proteins, GAB-1,(3,4) Shc(5) and c-Cbl(6) (see Fig. 1). Each of these substrates recruits a distinct subset of signaling protein containing SH2 domains, in a phosphotyrosine-dependent manner.(2,7,8) Once phosphorylated, the substrate Shc interacts with the adapter protein Grb2, leading to activation of the Ras/Raf/Map kinase pathway.(9) GAB-1 phosphorylation also plays a role in MAP kinase activation, via the tyrosine phosphatase SHP-2.(10–12) Although there are multiple pathways for the activation of MAP kinase, the enzyme is similarly activated by other growth factors that are not insulinomimetic, and is neither necessary nor sufficient for the metabolic actions of insulin.(13,14)

Most attention in the field of insulin receptor substrates has focused on the IRS family of proteins. The tyrosine phosphorylation of IRS proteins generates docking sites for a number of SH2-containing proteins.(2) The predominant partner, however, seems to be the p85 regulatory subunit of the type 1A PI 3-kinase.(15) PI 3-kinase catalyzes the formation of phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3), which

![Figure 1](image.png)

**Figure 1.** The insulin receptor tyrosine kinase substrates and downstream signaling pathways. Upon insulin binding, the insulin receptor undergoes autophosphorylation on tyrosine residues within the β-chain of the receptor, recruiting substrate proteins (IRS1-4, Gab1 and Shc) that are tyrosine phosphorylated. Phosphorylation of c-Cbl requires the adapter protein CAP for the recruitment to the insulin receptor. Once phosphorylated, these substrates engage a variety of effector proteins via SH2 domain interactions, including the tyrosine phosphatase SHP2, the adapters crk and Grb2 and the p85 regulatory subunit of PI 3-kinase. Activation or localization of these proteins initiates multiple signaling pathways that regulate diverse functions including metabolic activity, growth and differentiation.
serves as an allosteric regulator of the phosphoinositide-dependent kinase (PDK). PDK can in turn phosphorylate and activate protein kinase B (PKB/Akt) as well as the atypical protein kinase C isoforms PKCζ and PKCδ. Although there is substantial controversy regarding the potential roles of either PKB/Akt or PKCζ, in insulin-stimulated Glut4 translocation, PI 3-kinase appears to be essential. Inhibition of PI 3-kinase activity with pharmacological inhibitors such as wortmannin, expression of dominant-interfering mutants, or microinjection of blocking antibodies can completely prevent the stimulation of glucose uptake and Glut4 translocation by insulin. Although these data demonstrate the necessity of PI 3-kinase, several lines of evidence indicate that activation of the enzyme is not sufficient. Dramatic overexpression of constitutively active mutants of PI 3-kinase can stimulate Glut4 translocation only partially. Other growth factors, such as PDGF and IL-4, or certain adhesion molecules, stimulate PI 3-kinase to an extent similar to that seen with insulin, but have only a minor effect on glucose uptake and Glut4 translocation by insulin, but can stimulate when cells are pretreated with insulin and a pharmacological inhibitor of PI 3-kinase. Furthermore, several studies have demonstrated that exercise, contraction and hypoxia can all induce glucose uptake and Glut4 translocation in skeletal muscle independent of any detectable PI 3-kinase activation. Taken together, these data suggest that insulin must generate at least two independent signals to stimulate glucose transport, one dependent on and another independent of PI 3-kinase. Moreover, the activation of PI 3-kinase by noninsulinomimetic hormones suggests that the second pathway must be unique for insulin. In this review, we will discuss the search for a second signaling pathway, and the potential role of spatial compartmentalization in the specificity of signal transduction in insulin action, particularly regarding the stimulation of glucose transport.

**Glucose transport and Glut4**

In mammalian tissues, insulin-stimulated glucose uptake is mediated by the facilitative transporter Glut4, a member of a family of related integral-membrane proteins. Glut4 is highly expressed in skeletal and cardiac muscle and adipose tissue. In the basal state, Glut4 slowly recycles between the plasma membrane and vesicular compartments within the cell, where most of the Glut4 resides. Upon insulin stimulation, Glut4 rapidly translocates to the plasma membrane, through a process of targeted exocytosis. At the same time, Glut4 endocytosis is attenuated, resulting in a dramatic increase in glucose uptake.

Although there is substantial evidence that Glut4 exists in specialized vesicles sequestered within the cell, the precise intracellular location and trafficking pathways of these vesicles are unclear. Immunelectron microscopy has demonstrated the predominant localization of Glut4 in tubulovesicular and vesicular structures, with the some of the protein localized to clathrin-coated vesicles, endosomal structures and the trans-Golgi network. The Glut4 vesicle appears to be biochemically distinct from the vesicles of the recycling endosomal network, which contain the Glut1 transporter as well as the transferrin and mannose 6-phosphate receptors. Furthermore, the Glut4 compartment is enriched in the v-SNARE (soluble N-ethylmaleimide sensitive factor attachment protein) protein VAMP2 but not the related VAMP3/cellubrevin isoform that is present in the recycling endosome.

This specific compartmentalization of Glut4 provides a mechanism by which insulin can stimulate robust translocation of Glut4 to the plasma membrane, while only mildly stimulating the translocation of recycling proteins (Fig. 2). Although the mechanism of intracellular tethering of the Glut4 vesicle in resting cells is unknown, sequestration of Glut4 is dependent on C-terminal sequences in the protein. Overexpression of the N terminus of IRAP, which has significant homology to the C terminus of Glut4, results in Glut4 localization to the plasma membrane. These results suggest that both the C terminus of Glut4 and the N terminus of IRAP contribute to the cytoplasmic sequestration of Glut4 vesicle. However, the cytoplasmic targets of IRAP and Glut4 are unknown. One potential site for Glut4 tethering is the actin cytoskeleton. Insulin stimulates cytoskeletal rearrangement, possibly through the activation of proteins known to regulate actin polymerization, such as effectors of the Rho family of small G-proteins. In this regard, depolymerization of the actin cytoskeleton potently inhibits Glut4 translocation. Interestingly, the C-terminal domain of Glut4 can interact with the glycolytic enzyme aldolase. Aldolase can also bind to actin, and substrates of aldolase can mediate the dissociation of the Glut4–aldolase complex, potentially providing a negative feedback signal for glucose transport. Thus aldolase may mediate the interaction between Glut4 and the cytoskeleton.

Substantial evidence suggests that the plasma membrane target for the GLUT4 vesicle is the t-SNARE, syntaxin 4 (Syn4). Thus, the docking of the vesicle may be mediated by the interaction of Syn4 with the Glut4 vesicle v-SNARE protein, VAMP2. This interaction is reminiscent of the v-SNARE/t-SNARE interaction seen in synaptic vesicle exocytosis, suggesting that Glut4 exocytosis may occur through mechanisms similar to those proposed for synaptic vesicle transport. Several proteins have been demonstrated to bind to Syn4, including SNAP23, Munc18c and, more recently, Synip, to regulate the docking and fusion of VAMP2-containing GLUT4 vesicles. Among these, Synip has been shown to undergo an insulin-dependent release from Syn4, allowing VAMP2 to bind to the protein.
Compartmentalized PI 3-kinase activation in the regulation of Glut4 translocation by insulin

As mentioned above, it is likely that at least two signaling pathways are required for the stimulation of Glut4 translocation in response to insulin. PI 3-kinase and its downstream effectors are a necessary component of insulin-stimulated Glut4 translocation. Pharmacological inhibitors of PI 3-kinase, such as wortmannin, (18) or microinjection of dominant interfering constructs containing the p85 regulatory subunit of PI 3-kinase, (20) block insulin-stimulated Glut4 translocation. Moreover, microinjection of the inositol phosphatase SHIP2 that specifically removes the phosphate from PIP3 blocks insulin action. (50) Overexpression of PI 3-kinase or its downstream targets Akt and PKC \( \alpha / \lambda \), in cell culture models increased glucose uptake independent of insulin. (21,51–56) Moreover, in a recent study of type 2 diabetic patients, PI 3-kinase activation was impaired compared to normal subjects. (57)

Further evidence for an important role for PI 3-kinase has emerged from studies on the IRS proteins. Mutation of the insulin receptor at tyrosine 960, the docking site of IRS proteins, abolishes insulin-stimulated glucose transport. (58) Mice lacking the IRS-1 protein are insulin resistant, but do not develop diabetes unless crossed to mice in which another signaling molecule has been disrupted. (59–63) Animals lacking IRS-2 exhibit both impaired glucose uptake and diabetes. (64) However, the diabetic phenotype results from a defect in insulin secretion as well as insulin resistance. The mechanism of PI 3-kinase activation via IRS is distinct from that of other tyrosine kinase receptors, such as PDGF and EGF, which recruit PI 3-kinase directly to their receptors. This suggests that the IRS proteins uniquely activate PI 3-kinase via the recruitment of the enzyme to specific sites at or distal to the plasma membrane, perhaps to intracellular membranes. (22,65–67)

The formation of PIP3 by PI 3-kinase leads to the activation of a number of protein kinases. PIP3 appears to mediate the translocation of Akt to the plasma membrane, via its pleckstrin homology (PH) domain. (68) PKC\( \alpha / \lambda \) and phosphoinositide-dependent kinase 1 (PDK1) translocate to the plasma membrane by this same mechanism. Once at the plasma membrane, Akt and PKC\( \alpha / \lambda \) are phosphorylated and activated by PDK1. Although there are data to support an essential role for these kinases in glucose transport, the precise identity of the physiologically relevant kinase remains uncertain. (54,57)
Also uncertain is whether these protein kinases migrate to new sites upon activation, or whether there is local activation that impacts on Glut4 translocation. Moreover, as of yet, there is no information regarding the protein substrates that might be involved in Glut4 translocation, although there is speculation that this phosphorylation event might regulate the release of the vesicle from intracellular tethering sites.

Other downstream effectors of PIP3 formation have also been implicated in glucose transport. A class of proteins, including GRP1/ARNO, which contain PH domains and Sec7 guanine nucleotide exchange domains for ARF proteins, are recruited to the plasma membrane after insulin stimulation.(69–72) The ARF proteins are involved in vesicle movement and may be involved in insulin-stimulated membrane ruffling. Recently, one downstream target of ARF, phospholipase D, was demonstrated to colocalize with the Glut4 vesicle and to potentiate the effects of insulin on Glut4 translocation.(73) It remains unclear, however, whether insulin regulates the activity of phospholipase D. One other potential target for PI 3-kinase is the small GTPase Rab4. Rab4 compartmentalizes with the Glut4 vesicle and redistributes the cytosolic fraction upon insulin stimulation.(74,75) Overexpression of Rab4 leads to an inhibition of insulin-stimulated Glut4 translocation, suggesting that Rab4 is an important regulator of the mobility of the Glut4 vesicle.(74)

**PI 3-kinase-independent pathways in the regulation of glucose transport**

A potential clue towards identifying the PI 3-kinase-independent arm of insulin action came from the idea that signal initiation might be segregated into compartments in the plasma membrane. One candidate for such a compartment are caveolae, small invaginations of the plasma membrane that are enriched in lipid-modified signaling proteins, GPI-anchored proteins, glycolipids, sphingolipids and cholesterol.(76) Insulin stimulates the tyrosine phosphorylation of caveolin, the major structural protein in caveolae.(77,78) Investigation into this pathway revealed that it was downstream of the phosphorylation of another insulin receptor substrate, the protooncogene c-Cbl.(78) The insulin-stimulated phosphorylation of Cbl occurs only in metabolically responsive cell lines, and not in other fibroblast lines, despite the presence of Cbl and an active receptor.(6) These findings led us to search for an adapter protein that might recruit Cbl to the insulin receptor, to explain its phosphorylation only in certain cells. The Cbl-associated protein (CAP) was identified in a two-hybrid screen using Cbl as bait.(79) CAP contains three carboxyl terminal SH3 domains, one of which mediates its binding to Cbl. It is expressed predominantly in insulin sensitive tissues and in differentiated 3T3-L1 adipocytes. Interestingly, the CAP gene is upregulated by the insulin-sensitizing thiazolidinediones (TZDs).(80) TZD activation of the nuclear receptor PPARγ directly activates the transcription of CAP through a PPARγ response element in the promoter of the CAP gene.(81) Moreover, TZD-stimulated increases in CAP expression lead to a more robust phosphorylation of Cbl in response to insulin, establishing a potential primary link between TZD-induced insulin sensitization and insulin signal transduction.

The CAP protein recruits Cbl to the insulin receptor in untreated cells. Upon Cbl phosphorylation, a portion of the Cbl/CAP complex is released from the receptor and, subsequently, accumulates in a triton-insoluble plasma membrane domain enriched in caveolae or lipid rafts.(78) The insulin-stimulated phosphorylation of Cbl and its localization to the lipid raft is independent of PI 3-kinase.

The concentration of CAP in lipid rafts appears to result from its association with the caveolar protein flotillin,(82,83) A dominant interfering mutant of CAP that binds to flotillin, but not c-Cbl, interferes with this localization of Cbl to lipid rafts (Fig. 3). Moreover, this mutant specifically blocks insulin-stimulated Glut4 translocation and glucose uptake.(83) Once phosphorylated, Cbl can recruit the SH2-containing adapter protein CRKII to the lipid raft, along with the guanine nucleotide exchange factor C3G. Although the precise target of C3G in the lipid raft is uncertain, recent data suggest that it may activate the rho family protein TC10.(85) This G protein is expressed in fat and muscle, and can be acutely activated by insulin in a CAP-dependent but PI 3-kinase-independent manner.(84) Although the physiologically relevant effectors that interact with TC10 are unknown, disruption of its activation blocks insulin-stimulated glucose transport and Glut4 translocation.(84)

Although the targets of the PI 3-kinase and CAP pathways are uncertain, one likelihood is that they regulate different processes. For example, PIP3-dependent kinases may phosphorylate proteins involved in the tethering of the Glut4 vesicle at intracellular sites, leading to the release and default trafficking of the vesicle to the plasma membrane. On the contrary, the CAP/TC10 pathway may regulate processes involved in the docking and fusion of the vesicle at the plasma membrane. One potential target of this pathway is the syntaxin 4 binding partner Synip.(49) In the basal state, Synip inhibits the interaction of VAMP2 in the Glut4 vesicle with the syntaxin 4/SNAP-23 t-SNARE complex in the plasma membrane. Insulin stimulates the disassociation of Synip from syntaxin 4, permitting Syn4–VAMP2 binding, followed by docking and subsequent fusion of the Glut4 vesicle with the plasma membrane. The insulin-stimulated dissociation of Synip from syntaxin 4 is not blocked by wortmannin.

**Future prospects**

Although it is clear that multiple signaling pathways are required for the stimulation of glucose transport by insulin, the ultimate targets of these pathways, and the biochemical changes in these targets remain unexplored. Additionally, the
relative importance of these pathways in different tissues, and their role in mediating other aspects of insulin action on metabolic enzymes, other transport processes, or gene expression have not been evaluated. Most importantly, it will be critical to fully evaluate the structure and functions of the individual components of these pathways in animal models of insulin resistance, as well as in muscle and fat from patients with insulin resistance and type 2 diabetes.

References


64. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998;391:900–904.


84. Chiang SH, Baumann CA, Kanzaki, M, Thurmond DC, Neudauer CL, Macara IG, Pessin JE, Saitel, AR. Insulin-stimulated GLUT4 translocation requires the CAP dependent activation of the small GTP binding protein TC10 (in press).